Compare PGEN & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | ATRC |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2013 | 2005 |
| Metric | PGEN | ATRC |
|---|---|---|
| Price | $3.81 | $26.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $8.33 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 4.0M | 801.6K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.74 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $230,981,000.00 | $201,630,000.00 |
| Revenue This Year | $1,115.92 | $15.27 |
| Revenue Next Year | $81.04 | $12.21 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.40 |
| 52 Week Low | $1.30 | $25.36 |
| 52 Week High | $5.47 | $43.18 |
| Indicator | PGEN | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 38.10 | 38.88 |
| Support Level | $3.49 | N/A |
| Resistance Level | $4.40 | $30.49 |
| Average True Range (ATR) | 0.29 | 1.29 |
| MACD | -0.07 | -0.20 |
| Stochastic Oscillator | 2.97 | 18.34 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.